Preclinical Approaches to the Protection of Ovarian Function


Introduction

Recent advances in our understanding of the mechanisms underlying the impact of cytotoxic drugs on the ovary have opened up new directions for the protection of ovarian function from chemotherapy-induced damage. Studies are providing greater detail as to the pathways and factors triggered within the different cell types of the ovary by each drug class. As we gain increased knowledge of the specifics of these pathways, we reveal new targets for protective agents to reduce or prevent ovarian damage.

Most preclinical research on protective agents has concentrated on drug groups known clinically to have severe effects on follicle reserve, such as alkylating agents (cyclophosphamide, busulfan and dacarbazine), platinum complexes (cisplatin, carboplatin) and taxanes (paclitaxel). A large number of studies have also examined the anthracyclin antibiotic doxorubicin (DXR), which has been shown to affect the follicle reserve experimentally but which is currently considered of low clinical risk for premature ovarian insufficiency (POI). Alkylating agents and platinum complexes work in a similar fashion, creating DNA crosslinks, which, in turn, cause DNA breaks, ultimately triggering apoptosis. The taxanes are microtubule-stabilizing agents, as distinct from DNA-damaging drugs, but it has been demonstrated that paclitaxel acts via Bax to induce apoptosis. DXR is an intercalating agent that blocks DNA replication and causes double-stranded (ds)DNA breaks; it induces apoptosis primarily in the stroma and granulosa cells of growing follicles. Within the oocyte, anthracyclin agents such as DXR have been shown to induce chromosomal fragmentation as well as fragmentation of the cytoplasm into apoptotic bodies.

Ovarian Protection by Affecting Apoptotic Pathways

The most extensively researched pathway in the context of chemotherapy- and radiotherapy-induced ovarian injury is the apoptotic pathway leading to cell death in response to DNA damage. Cytotoxic drug-induced apoptosis has been most clearly demonstrated in growing follicles ( Figure 9.1B ), and has been shown to originate in the proliferating granulosa cells. Within the mature oocyte, apoptosis is mediated by several molecules including ceramide, Bax, and the caspases. Ceramide has been identified as an initiator of DXR-induced apoptosis in oocytes, and Bax, a protein produced by the Bcl2-gene family, plays an essential role in DXR-initiated apoptosis in mature mouse oocytes. Caspases, members of the CASP protease family, have been universally shown to play a pivotal role as cell death effector molecules, and are central in the apoptotic pathway of mature oocytes. Caspases-2, -12 and -3 specifically, have been shown to play a role in apoptosis of mature oocytes. Mouse oocytes pretreated with a caspase inhibitor as well as mature oocytes derived from mice that lack expression of caspase-2 show a marked resistance to DXR-induced apoptosis.

Figure 9.1, (A) Apoptosis pathways in the ovary and anti-apoptotic agents.

Investigation of apoptotic pathways within the dormant primordial follicle have revealed that p63, a homologue of anti-oncogene p53, found in the nucleus of oocytes, and specifically the p63 isoform TAp63, is a key mediator of the DNA damage apoptosis pathway in the response of primordial follicle oocytes to DNA injury. The p63 pathway is upregulated when oocytes are exposed to external triggers of DNA damage such as radiation and chemotherapy drugs such as cisplatin, and loss of p63 in mouse oocytes results in resistance to the apoptotic effects of radiation and cisplatin. Tap63 activates apoptosis via proteins BAX (Bcl-2-associated X protein) and BAK (Bcl-2 homologous antagonist killer). The activation of apoptosis is mediated by TAp73, either directly or through the activation of p53 upregulated modulator of apoptosis (PUMA) and phorbol-12-myristate-13-acetate-induced protein 1 (NOXA). Oocyte-specific deletion of PUMA and/or both PUMA and NOXA in mice prevents γ-irradiation-induced apoptosis and can produce healthy offspring, indicating that the protected oocytes are capable of DNA repair and subsequent normal function. Figure 9.1 schematically summarizes the key factors in the relevant apoptotic pathways.

Each of these factors in the apoptotic cascade represents a potential target for blocking the effects of cytotoxic treatments on the ovary. One important concern with developing any agent that interferes with the apoptotic pathway as a potential protectant is that, since induction of apoptosis is a key anticancer action of many of the chemotherapy drug classes, interference with the apoptotic pathway may inhibit the anticancer effects of these drugs. A further concern is that blocking apoptosis in DNA-damaged oocytes could allow survival of germ cells that are beyond the repair capabilities of the DNA repair molecules. Fertilization of these genetically compromised oocytes could lead to an increased risk of miscarriage, fetal death or malformation.

Imatinib

c-Abl protein tyrosine kinase has been shown to act as a “switch” for TAp63 transcriptional activity and the apoptotic pathway following exposure to the chemotherapy agents cisplatin and DXR. Other studies have further demonstrated that c-Abl plays a role in the maintenance of genomic integrity by dealing with DNA breaks in both meiotic and mitotic cells. Imatinib is a competitive tyrosine kinase inhibitor clinically used in the treatment of cancer, most notably chronic myelogenous leukaemia. It was investigated as an agent to prevent primordial follicle loss caused by cisplatin based on its role as a c-Abl kinase inhibitor. Results from that study demonstrated that co-administration of imatinib with cisplatin in mice reduced primordial follicle loss as well as improving fertility and reproductive outcomes. However, a subsequent study contested these results, finding that imatinib neither protected primordial follicle oocytes from cisplatin-induced apoptosis nor prevented loss of fertility in two independent strains of mice. The conflicting results are likely due to a number of key differences in study design, but the role of c-Abl in the induction of oocyte degeneration has since been supported using another c-Abl inhibitor, GNF-2, while others have confirmed the protective effect of imatinib. An in vitro study demonstrated that imatinib reduced the adverse effect of cisplatin on follicle health in cultured ovaries, while Kim et al. showed that imatinib inhibited the cisplatin-induced upregulation of apoptotic mediators and reduced the damage to primordial follicles in a novel system of in vitro organ culture followed by subrenal grafting that enabled assessment of longer term effects.

Additional study is needed both to ascertain whether imatinib interferes with the anticancer action of cisplatin, since c-Abl has been shown to mediate cisplatin’s action in a number of cancer cell lines, and also to assess the genetic integrity of oocytes rescued from apoptosis.

Sphingosine-1-Phosphate

Sphingomyelin hydrolysis is a ceramide-promoted trigger of apoptotis and sphingosine-1-phosphate (S1P) is an inhibitor of this particular apoptotic pathway. In vivo treatment of human ovarian tissue xenografts in mice with S1P increased vascular density and angiogenesis, and reduced follicle apoptosis. In vivo administration of S1P before radiation exposure resulted in a dose-dependent preservation of follicle numbers in mice, and a virtually complete preservation of both primordial and growing follicles when S1P was administered at high doses. In similar studies, S1P pretreatment was shown to reduce irradiation-induced primordial follicle depletion in rats, primates, and xenografted human ovarian tissue.

S1P pretreatment demonstrated a protective effect in mice treated with dacarbazine, reducing follicle loss and increasing pregnancy rates. Pretreatment and ongoing administration of S1P to mice carrying xenografted human ovarian tissue prevented the significant apoptosis of follicles caused by both cyclophosphamide (Cy) and DXR treatment. Ex vivo , S1P treatment of mouse oocytes conferred resistance to DXR-induced apoptosis. Results have not been uniformly positive, however, with one study reporting no reduction in Cy-induced follicle loss in S1P-treated rats.

One limitation of S1P is that, because of its very short plasma half-life, it cannot be administered by systemic injection, and would either require continuous administration (studies used mini-osmotic pumps) or injections directly into the ovary. Local administration would, in theory, reduce the possibility that S1P would interfere with the therapeutic effects of chemotherapy drugs. Studies that have examined offspring derived from female mice and macaques that received S1P treatment prior to radiation showed no significant abnormalities of any kind, possibly allaying concerns regarding persistent DNA damage in rescued oocytes, but no equivalent studies have been conducted after chemotherapy treatment.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here